Amino Alcohol- (NPS-2143) and Quinazolinone-Derived Calcilytics (ATF936 and AXT914) Differentially Mitigate Excessive Signalling of Calcium-Sensing Receptor Mutants Causing Bartter Syndrome Type 5 and Autosomal Dominant Hypocalcemia
Open Access
- 15 December 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e115178
Abstract
Activating calcium sensing receptor (CaSR) mutations cause autosomal dominant hypocalcemia (ADH) characterized by low serum calcium, inappropriately low PTH and relative hypercalciuria. Four activating CaSR mutations cause additional renal wasting of sodium, chloride and other salts, a condition called Bartter syndrome (BS) type 5. Until today there is no specific medical treatment for BS type 5 and ADH. We investigated the effects of different allosteric CaSR antagonists (calcilytics) on activating CaSR mutants. All 4 known mutations causing BS type 5 and five ADH mutations were expressed in HEK 293T cells and receptor signalling was studied by measurement of intracellular free calcium in response to extracellular calcium ([Ca2+]o). To investigate the effect of calcilytics, cells were stimulated with 3 mM [Ca2+]o in the presence or absence of NPS-2143, ATF936 or AXT914. All BS type 5 and ADH mutants showed enhanced signalling activity to [Ca2+]o with left shifted dose response curves. In contrast to the amino alcohol NPS-2143, which was only partially effective, the quinazolinone calcilytics ATF936 and AXT914 significantly mitigated excessive cytosolic calcium signalling of all BS type 5 and ADH mutants studied. When these mutants were co-expressed with wild-type CaSR to approximate heterozygosity in patients, ATF936 and AXT914 were also effective on all mutants. The calcilytics ATF936 and AXT914 are capable of attenuating enhanced cytosolic calcium signalling activity of CaSR mutations causing BS type 5 and ADH. Quinazolinone calcilytics might therefore offer a novel treatment option for patients with activating CaSR mutations.Keywords
This publication has 33 references indexed in Scilit:
- AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal womenBone, 2014
- A HomozygousCaSRMutation Causing a FHH Phenotype Completely Masked by Vitamin D Deficiency Presenting as RicketsThe Journal of Clinical Endocrinology & Metabolism, 2014
- Mutations Affecting G-Protein Subunit α11in Hypercalcemia and HypocalcemiaNew England Journal of Medicine, 2013
- CaSR function in the intestine: Hormone secretion, electrolyte absorption and secretion, paracrine non-canonical Wnt signaling and colonic crypt cell proliferationBest Practice & Research Clinical Endocrinology & Metabolism, 2013
- Extracellular calcium sensing and signallingNature Reviews Molecular Cell Biology, 2003
- Functional Characterization of a Calcium-Sensing Receptor Mutation in Severe Autosomal Dominant Hypocalcemia with a Bartter-Like SyndromeJournal of the American Society of Nephrology, 2002
- Association between activating mutations of calcium-sensing receptor and Bartter's syndromeThe Lancet, 2002
- Activating Mutations of the Calcium-Sensing Receptor: Management of HypocalcemiaThe Journal of Clinical Endocrinology & Metabolism, 2001
- Calcilytic Compounds: Potent and Selective Ca2+Receptor Antagonists That Stimulate Secretion of Parathyroid HormoneThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic ratsJournal of Clinical Investigation, 2000